Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8098647
Reference Type
Journal Article
Title
Clinical use of carvedilol compared to nifedipine in the treatment of mild to moderate essential hypertension
Author(s)
Plavnik, FL; Freitas, AF; Portela, JE; Dantas, M; Spritzer, T; Kohlmann, NEB; Spritzer, N; Furtado, MR; Kohlmann Jr, O
Year
1994
Is Peer Reviewed?
0
Journal
Arquivos Brasileiros de Cardiologia
ISSN:
0066-782X
EISSN:
1678-4170
Volume
63
Issue
5
Page Numbers
405-408
Language
Portuguese
Abstract
Purpose - To compare the efficacy of carvedilol, a new antihypertensive drug that combines vasodilatory and β-blocker properties, with nifedipine. Methods - In a multicenter double-blind trial, 106 mild to moderate essential hypertensive patients were treated with either carvedilol (n = 51), or nifedipine (n = 55) as monotherapy. Following 4 weeks of wash-out/run-in period, patients from the carvedilol group received this drug once a day at a dosage of 25 mg/day for 8 consecutive weeks. In order to maintain the double-blind character of the study, a placebo was administered in the carvedilol group at identical dosage intervals as used in the nifedifine s.r. group. Nifedipine was also administered for 8 weeks at a dosage of 40 mg/day given b.i.d. Results - Both treatments were equally efficient in reducing blood pressure in the seated and upright positions. Blood pressure response to treatment was obtained in 79% and 78% of patients treated with carvedilol and nifedipine, respectively. The carvedilol group did not develop reflex tachycardia which is usually seen when prescribing vasodilators. Blood biochemistry remained unchanged with both treatments. Besides similar blood pressure efficacy, side effects by patients taking carvedilol were less frequent than nifedipine group. Conclusion - Carvedilol is a safe, efficient, once/day choice as monotherapy for mild to moderate essential hypertensive patients.
Keywords
carvedilol; essential hypertension; nifedipine
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity